NASDAQ:FLGT Fulgent Genetics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fulgent Genetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $31.72 -0.63 (-1.95 %) (As of 09/17/2020 12:00 AM ET) Add Compare Share Today's Range$30.38Now: $31.72▼$31.9950-Day Range$25.66MA: $34.93▼$50.5152-Week Range$6.70Now: $31.72▼$52.47Volume392,324 shsAverage Volume526,480 shsMarket Capitalization$701.49 millionP/E Ratio264.36Dividend YieldN/ABeta1.9 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.72, Fulgent Genetics has a forecasted upside of 6.3% from its current price of $31.72.Amount of Analyst CoverageFulgent Genetics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesFulgent Genetics has received 219 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFulgent Genetics has received 247 “underperform” votes. (Add your “underperform” vote.)Community SentimentFulgent Genetics has received 53.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote “Outperform” if you believe FLGT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,727,923.00 in company stock.Percentage Held by Insiders45.00% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.08% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow by 55.14% in the coming year, from $1.07 to $1.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is 264.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is 264.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.84.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLGT Previous Symbol CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone626-350-0537Debt Debt-to-Equity Ratio0.03 Current Ratio6.33 Quick Ratio6.33Price-To-Earnings Trailing P/E Ratio264.36 Forward P/E Ratio29.64 P/E GrowthN/A Sales & Book Value Annual Sales$32.53 million Price / Sales21.56 Cash Flow$0.15 per share Price / Cash Flow205.59 Book Value$4.42 per share Price / Book7.18Profitability EPS (Most Recent Fiscal Year)$0.02 Net Income$-410,000.00 Net Margins5.78% Return on Equity5.05% Return on Assets4.61%Miscellaneous Employees123 Outstanding Shares22,115,000Market Cap$701.49 million Next Earnings Date11/2/2020 (Estimated) OptionableNot Optionable $31.72 -0.63 (-1.95 %) (As of 09/17/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FLGT News and Ratings via Email Sign-up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter. Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions How has Fulgent Genetics' stock price been impacted by COVID-19? Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FLGT shares have increased by 205.5% and is now trading at $30.73. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Fulgent Genetics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fulgent Genetics. When is Fulgent Genetics' next earnings date? Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Fulgent Genetics. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics Inc (NASDAQ:FLGT) issued its earnings results on Tuesday, August, 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.16. The business earned $17.27 million during the quarter, compared to analysts' expectations of $14.52 million. Fulgent Genetics had a net margin of 5.78% and a return on equity of 5.05%. View Fulgent Genetics' earnings history. What guidance has Fulgent Genetics issued on next quarter's earnings? Fulgent Genetics issued an update on its FY 2020 After-Hours earnings guidance on Monday, August, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-135 million, compared to the consensus revenue estimate of $121.56 million. What price target have analysts set for FLGT? 6 Wall Street analysts have issued 1 year price targets for Fulgent Genetics' shares. Their forecasts range from $11.00 to $75.00. On average, they anticipate Fulgent Genetics' share price to reach $33.72 in the next year. This suggests a possible upside of 9.7% from the stock's current price. View analysts' price targets for Fulgent Genetics. Are investors shorting Fulgent Genetics? Fulgent Genetics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,180,000 shares, an increase of 27.3% from the August 15th total of 926,900 shares. Based on an average daily volume of 802,300 shares, the short-interest ratio is currently 1.5 days. Approximately 10.6% of the shares of the stock are sold short. View Fulgent Genetics' Short Interest. Who are some of Fulgent Genetics' key competitors? Some companies that are related to Fulgent Genetics include Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), RadNet (RDNT), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), DermTech (DMTK), Centogene (CNTG), Enzo Biochem (ENZ), Biocept (BIOC), Anpac Bio-Medical Science (ANPC), Celcuity (CELC) and Miragen Therapeutics (MGEN). View all competitors. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Inseego (INSG), Marvell Technology Group (MRVL), NeoGenomics (NEO), Square (SQ), InVitae (NVTA), Docusign (DOCU), JD.Com (JD) and Teladoc Health (TDOC). Who are Fulgent Genetics' key executives? Fulgent Genetics' management team includes the following people: Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)Mr. Paul Kim, Chief Financial Officer (Age 52)Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52) When did Fulgent Genetics IPO? (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. What is Fulgent Genetics' stock symbol? Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT." Who are Fulgent Genetics' major shareholders? Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Trust N.A. (3.63%), Russell Investments Group Ltd. (2.19%), Old West Investment Management LLC (1.33%), Bank of Montreal Can (1.00%), Essex Investment Management Co. LLC (0.76%) and Cadence Capital Management LLC (0.35%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Ming Hsieh and Paul Kim. View institutional ownership trends for Fulgent Genetics. Which major investors are selling Fulgent Genetics stock? FLGT stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, Cadence Capital Management LLC, Bank of Montreal Can, Old West Investment Management LLC, Mutual Advisors LLC, ClariVest Asset Management LLC, Two Sigma Advisers LP, and Cornerstone Investment Partners LLC. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim. View insider buying and selling activity for Fulgent Genetics. Which major investors are buying Fulgent Genetics stock? FLGT stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Trust N.A., Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, and Virtu Financial LLC. View insider buying and selling activity for Fulgent Genetics. How do I buy shares of Fulgent Genetics? Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Fulgent Genetics' stock price today? One share of FLGT stock can currently be purchased for approximately $30.73. How big of a company is Fulgent Genetics? Fulgent Genetics has a market capitalization of $679.59 million and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe. What is Fulgent Genetics' official website? The official website for Fulgent Genetics is www.fulgentgenetics.com. How can I contact Fulgent Genetics? Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
